Cargando…
Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers
Hepatic drug metabolizing enzymes (DMEs), whose activity may be affected by liver diseases, are major determinants of drug pharmacokinetics. Hepatitis C liver samples in different functional states, i.e., the Child–Pugh class A (n = 30), B (n = 21) and C (n = 7) were analyzed for protein abundances...
Autores principales: | Drozdzik, Marek, Lapczuk-Romanska, Joanna, Wenzel, Christoph, Skalski, Lukasz, Szeląg-Pieniek, Sylwia, Post, Mariola, Parus, Arkadiusz, Syczewska, Marta, Kurzawski, Mateusz, Oswald, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002520/ https://www.ncbi.nlm.nih.gov/pubmed/36901973 http://dx.doi.org/10.3390/ijms24054543 |
Ejemplares similares
-
Protein Abundance of Drug Transporters in Human Hepatitis C Livers
por: Droździk, Marek, et al.
Publicado: (2022) -
Gene Expression and Protein Abundance of Hepatic Drug Metabolizing Enzymes in Liver Pathology
por: Drozdzik, Marek, et al.
Publicado: (2021) -
Hepatic drug-metabolizing enzymes and drug transporters in Wilson’s disease patients with liver failure
por: Szeląg-Pieniek, Sylwia, et al.
Publicado: (2021) -
The reference liver—CYP450 and UGT enzymes in healthy donor and metastatic livers: the impact of genotype
por: Kurzawski, Mateusz, et al.
Publicado: (2021) -
Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
por: Droździk, Marek, et al.
Publicado: (2020)